(PharmaNewsWire.Com, January 07, 2017 ) The generic drugs market has seen rapid expansion for more than 30 years, and consistently achieves higher annual growth rates than the overall pharmaceutical market. The increase in generic drug activity can be primarily attributed to the promise of significant revenues from blockbuster drugs nearing patent expiry. In the US – the largest generic drugs market by revenue – the number of generic drug approvals hit a record high in 2015, due to a new program that aimed to speed up approvals. There has also recently been a surge in the number of industry-transforming mergers and acquisitions, with companies looking to consolidate their position in this highly lucrative market.
The results of GBI’s latest industry survey provide insightful analyses from different expert panels, including R&D and commercial, and highlight trends observed in key geographical markets. The survey examined key commercial issues and recent developments in the generic drugs market, such as the reasons behind the surge in mergers and acquisitions, and the likely effects on market dynamics. It covered important factors currently driving or restraining the market, prospects for key therapy areas expected to exhibit significant levels of genericization in the coming years, and the most promising emerging markets for generic companies in terms of revenue potential. Additionally, the survey examined common business strategies and regulations being leveraged by global generic drug companies for market expansion.
Gain insightful analyses and understanding of market dynamics: This report comprehensively describes and assesses the most important factors driving and restraining the generic drugs market. It assesses pertinent commercial and regulatory aspects of the industry by combining survey results with proprietary in-house expertise and extensive secondary research efforts.
Assess the generic drugs pipeline for top small molecule drugs in the market: Our study provides prospects for these drugs beyond their patent expiries, including potential generic competition, expected launch dates and revenue forecasts to 2021.
Evaluate the strategies used by companies to promote generic drug usage: This report provides insights regarding the various commercial strategies being adopted and leveraged by generic drug companies to promote their therapies.
Understand government policies and strategies to promote generic drug usage: This report assesses current strategies and regulations implemented by governments in key geographic markets to promote generic drug usage.
Gain insight on mergers and acquisitions in the global generic drugs market: This report describes industry-transforming mergers and acquisitions that have occurred in recent years, the reasons behind the recent surge in these types of transactions, and their likely impact on market dynamics.
Tables of Content:
Table 1: Generic Drugs by Type 9
Table 2: Generic Drug Entry Strategies 11
Table 3: Branded Drugs for which Authorized Generics Were Launched in US in 2015 38
Table 4: Selection of Branded Drugs for which First-Time Generics Have Been Launched in the US in 2015 39
Table 5: Super Generics Approved in the US, 2010–2014 40
Table 6: Super Generics Under Development in the US, 2016 41
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
